Novo Nordisk(US:NVO) 智通财经网·2025-07-30 00:34Company Insights - Novo Nordisk has lowered its full-year earnings guidance, with operating profit growth expectations revised from 16%-24% to 10%-16% due to lower-than-expected penetration of its weight loss drug Wegovy in cash payment channels, impacted by "unsafe and illegal large-scale counterfeit drugs" [2] - The stock price of Novo Nordisk fell by 21.81% following the announcement, leading to a decline in several U.S. pharmaceutical stocks [2] - Lakala's major shareholder, Legend Holdings, has reduced its stake by 5.3596 million shares, bringing its ownership down to 25.86% [14] Industry Insights - The China Photovoltaic Industry Association has issued a clarification regarding rumors about the multi-crystalline silicon sector, stating that the circulated information is significantly inaccurate [4] - The rumors were related to the "big collecting small" storage initiative, which involves multiple companies including Xinyi, Nanfang, Baofeng, Runyang, and Hosheng Silicon Industry [4] - The express delivery industry is expected to undergo a value reassessment as the State Post Bureau addresses "involution-style" competition, with potential price increases in response to regulatory calls [10]